However, several tumor types including HCC exert a profound resistance to TRAIL treatment, majorly due to the constitutive expression of intracellular TRAIL resistance-mediating factors, such as FADD-like interleukin-1β-converting enzyme (FLICE)-inhibitory protein (FLIP), in cancer cells [6, 7]. This evidence concerns the gene TNFSF10 and neoplasm.